Comparison of Higher-Dose Intradermal Hepatitis B Vaccination to Standard Intramuscular Vaccination of Healthcare Workers
- 1 April 2000
- journal article
- clinical trial
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 21 (4) , 264-269
- https://doi.org/10.1086/501756
Abstract
Objective.: To compare the immunogenicity of hepatitis B vaccine administered via intradermal (ID) versus intramuscular (IM) route.Methods: Subjects chose either to specify the route of immunization or to undergo random allocation to vaccination by the ID (0.15 mL) or the IM (1.0 mL) route. Yeast-derived recombinant hepatitis B vaccine was given at 0, 30, and 180 days. Hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb) were measured by microparticle enzyme immunoassay.Results: 763 subjects were enrolled. Baseline screening identified 65 subjects (8%) who were positive for HBsAb or HBcAb. Vaccination was completed by 590 (85%) of 698 enrollees (370 ID, 220 IM). Seroconversion rates (geometric mean titers [GMT]>0 IU/mL HBsAb) for those vaccinated ID were 99% and 96% for screening at 9 months and 1 year post-vaccination, respectively; subjects vaccinated intramuscularly had similar rates of 95% and 96%. Seropositivity rates (GMT ≥ 10 IU/mL HBsAb) showed a similar pattern, with 95%, 92%, and 73% at 9 months and 1 and 2 years, respectively, for those vaccinated ID, and 94%, 93%, and 81% for those having IM vaccination. GMT for HBsAb was significantly higher for individuals vaccinated IM than for those vaccinated ID (P<.0001). The GMT ratio for the IM and ID routes decreased over time, being 9.3 at 9 months, 7.8 at 1 year, and 5.9 at 2 years. An unanticipated side effect of intradermal vaccination was skin discoloration at injection sites, which persisted for at least 2 years postvaccination. Two thirds (112/166) of respondents reported that they would have selected the ID route despite the discoloration.Conclusions: Higher-dose ID vaccination (3 vs 1 μg per injection) uses one sixth of the dose required for standard IM vaccination. It is a cost-effective way to vaccinate populations against hepatitis B virus, but the long-term efficacy of the ID route must still be investigated.Keywords
This publication has 18 references indexed in Scilit:
- Intradermal hepatitis B vaccination in a 300-bed primary care hospital: Experience with a recombinant vaccine in a four-dose scheduleAmerican Journal of Infection Control, 1993
- Immunogenicity of Low-Dose Intradermal Recombinant DNA Hepatitis B VaccineSouthern Medical Journal, 1991
- Comparative Trial of Low-Dose, Intradermal, Recombinant- and Plasma-Derived Hepatitis B VaccinesThe Journal of Infectious Diseases, 1990
- Clinical experience with hepatitis B vaccinesAmerican Journal of Infection Control, 1989
- Immunogenisity of the intradermal route of hepatitis B vaccination with the use of recombinant hepatitis B vaccineAmerican Journal of Infection Control, 1989
- Hepatitis B Vaccine: Persistence of Antibody following ImmunizationInfection Control & Hospital Epidemiology, 1988
- Low dose intradermal vaccination against hepatitis B in mentally retarded patientsVaccine, 1988
- Intradermal hepatitis B vaccination in an abbreviated scheduleVaccine, 1986
- Clinical Evaluation of Low-Dose Intradermally Administered Hepatitis B Virus VaccineJAMA, 1985
- Hepatitis B Vaccine in Medical Staff of Hemodialysis UnitsNew England Journal of Medicine, 1982